The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.

Item
http://www.wikidata.org/entity/Q38919886
Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.Appendicitis caused by the metastasis of HER2-positive breast cancer.SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.Strategies and challenges for the next generation of antibody-drug conjugates.Protein based therapeutic delivery agents: Contemporary developments and challenges.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.Antibody-Drug Conjugates for Cancer Therapy.Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulationDNA damaging agent-based antibody-drug conjugates for cancer therapy
P2860

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.

Item
http://www.wikidata.org/entity/Q38919886
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The Preclinical Profile of the ...... ER2-Expressing Breast Cancers.
@en
type
label
The Preclinical Profile of the ...... ER2-Expressing Breast Cancers.
@en
prefLabel
The Preclinical Profile of the ...... ER2-Expressing Breast Cancers.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
The Preclinical Profile of the ...... ER2-Expressing Breast Cancers.
@en
P2093
P304
P31
P356
10.1158/1535-7163.MCT-14-0881-T
P433
P478
P577
P698